Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Abstract

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes play a major role, more and more new therapies for subgroups and histological subtypes are being developed, such as the use of PARP inhibitors to treat patients with BRCA mutations (breast and ovarian cancer). Supportive therapies are also evolving, allowing problems such as alopecia or nausea and vomiting to be treated more effectively. Treatment-related side effects have a direct impact on the prognosis of patients with metastatic breast cancer, and supportive therapy can improve compliance. Digital tools could be useful to establish better patient management systems. This overview provides an insight into recent trials and how the findings could affect routine treatment. Current aspects of breast cancer prevention are also presented.

• Authors: Andreas Schneeweiss, Michael P Lux, Wolfgang Janni, Andreas D Hartkopf, Naiba Nabieva, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Achim Wöckel, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Diethelm Wallwiener, Sara Y Brucker, Florian Schütz, Peter A Fasching, Tanja N Fehm
• Journal: Geburtshilfe und Frauenheilkunde (Geburtshilfe Frauenheilkd) Vol. 78 Issue 3 Pg. 246-259 (Mar 2018) ISSN: 0016-5751 [Print] Germany
• PMID: 29576630 (Publication Type: Journal Article)